NCT05385861 2025-08-15
Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET
National Health Research Institutes, Taiwan
Phase 1/2 Enrolling by invitation
Clinical Trials
3 trialsNCT07016737 2025-06-12
ESO-Nanjing12
Jiangsu Cancer Institute & Hospital
Phase 3 Enrolling by invitation
NCT06755515 2025-01-01
A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
Shandong New Time Pharmaceutical Co., LTD
Phase 2/3 Enrolling by invitation